Fabry disease
Rare human genetic lysosomal storage disorder
Ratings
0
Nobody has rated this yet. Be the first!
Subject of
15
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa
MALDI-TOF and cluster-TOF-SIMS imaging of Fabry disease biomarkers
Is the Alpha-Galactosidase A Variant p.Asp313Tyr (p.D313Y) Pathogenic for Fabry Disease? A systematic review
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease
The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial
Natural history and treatment of renal involvement in Fabry disease.
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
Fabry disease
Images in clinical medicine. Fabry's disease
Lists
0
